Laura J. Hamill serves as Independent Director of the Company. From August 2018 to July 2019, Ms. Hamill served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., a biotechnology company, where she was responsible for leading the company’s commercial operations. Prior to joining Gilead, Ms. Hamill held a number of U.S. and international executive positions at Amgen, Inc., a biopharmaceutical company, from July 2000 to July 2018, most recently as Senior Vice President, U.S. Commercial Operations. In addition, Ms. Hamill previously held a variety of roles in the biopharmaceutical industry, including positions at F. Hoffmann-La Roche Ltd., a biopharmaceutical company. Ms. Hamill holds a bachelor’s degree in business administration from the University of Arizona. Our board believes that Ms. Hamill’s extensive experience in the biopharmaceutical industry and leadership skills provides her with the qualifications and skills to serve our board of directors.
As the Independent Director of AnaptysBio Inc, the total compensation of Laura Hamill at AnaptysBio Inc is $204,246. There are 10 executives at AnaptysBio Inc getting paid more, with Hamza Suria having the highest compensation of $7,875,190.
Laura Hamill is 55, she's been the Independent Director of AnaptysBio Inc since 2019. There are 9 older and 5 younger executives at AnaptysBio Inc. The oldest executive at AnaptysBio Inc is Hollings Renton, 73, who is the Lead Independent Director.
Laura's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .
Over the last 8 years, insiders at AnaptysBio Inc have traded over $37,024,151 worth of AnaptysBio Inc stock and bought 5,919,575 units worth $115,520,117 . The most active insiders traders include Holdings A/S Novo, Capital, Llc Eco R1 a James N Topper. On average, AnaptysBio Inc executives and independent directors trade stock every 40 days with the average trade being worth of $4,143,306. The most recent stock trade was executed by Paul F. Lizzul on 14 August 2024, trading 2,000 units of ANAB stock currently worth $37,000.
founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c
AnaptysBio Inc executives and other stock owners filed with the SEC include: